November 4, 2021Open Access

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The findings of this international cohort study suggest that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, though ICI discontinuation owing to irAEs was more frequent with increasing age.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Caroline A. Nebhan

Vanderbilt University

Alessio Cortellini

Campus Bio Medico University Hospital

Weijie Ma

Tianjin University

Journals

JAMA Oncology

Actions

Institutions

Imperial College London

Dana-Farber Cancer Institute

The Ohio State University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study